Visionary Holdings (NASDAQ:GV) filed its audited financial statements for the fiscal year ended March 31, 2025, revealing a significant revenue decline as the company transitions away from its legacy education and real estate businesses toward a high-margin health and anti-aging platform.
The Toronto-based company reported total revenue of $5.04 million, a 46.2% decrease year-over-year.
The drop was largely attributed to a contraction in its real estate leasing segment and a shifting regulatory environment for education services in Canada.
However, management highlighted the first meaningful contributions from its "emerging health" segment, which generated $1.06 million (roughly 21% of total revenue).
This new division focuses on medical-grade anti-aging products, stem cell therapies, and premium medical aesthetics, primarily targeting the Asian market.
The company posted a net loss of $15.75 million for the year, pressured by $4.70 million in asset impairment charges and costs related to its corporate restructuring.
Meanwhile, financial stability remains a primary concern; Visionary disclosed a negative working capital of $54.50 million and several loan defaults.
To address these liquidity pressures, the firm is currently engaged in debt restructuring negotiations and pursuing fresh equity financing.